Eisai and Ajinomoto Pharmaceuticals launch LIVAMIN® to help reduce alcoholic liver diseases in the Philippines



In today’s high stakes world, alcohol has become an easily accessible social element and a widely accepted vice. The prolonged and relentless consumption of alcohol is a well-known risk factor for liver cirrhosis, a medical condition characterized by scarring of the liver, liver dysfunction and edema. Eisai Co., Ltd and Ajinomoto Pharmaceuticals Co., Ltd have announced the launch of LIVAMIN® Oral granules (Granules of Leucine, isoleucine and Valine), a branched-chain amino acid formula, in Philippines. Philippines currently ranks third in the list of the world’s heaviest drinkers with 9 million Filipinos suffering from Hepatitis B and Hepatitis C, all three contributing to the county’s liver disease epidemic.

The advanced stages of liver cirrhosis are marked by chronic hypoalbumenia, or low levels of albumin in blood serum. In simple words, albumin is a protein produced by the liver at 9 to 12g/day and this is what keeps your body running like a well-tuned car by maintaining a constant fluid pressure and transporting nutrients such as calcium and scavenging free-radicals. The low levels of albumin lead to edema which not only affects quality of life but also decisions pertaining to treatment in liver diseases. In April last year, Eisai’s subsidiary, HI-Eisai Pharmaceutical Inc. was granted approval in Philippines for distribution of LIVAMIN oral for amelioration of hypoalbumenia in patients with decompensated hepatic cirrhosis presenting with hypoalbumenia despite adequate dietary intake. Plans are currently in the works to launch LIVAMIN oral granules in Hong Kong and China with clinical trials to acquire regulatory approval presently underway. Here’s hoping to a future without liver disease.


Read more at: http://www.eisai.com/news/news201503.html